^
Association details:
Biomarker:TP53 mutation + KRAS mutation
Cancer:Lung Adenocarcinoma
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy

Published date:
11/21/2022
Excerpt:
...concomitant TP53 and KRAS mutations predicted a better PFS (p=0.015) and OS (p=0.029) compared with no mutations or a single mutation in either TP53 or KRAS.
DOI:
http://dx.doi.org/10.1136/jcp-2022-208574